ArticleWorld journal of gastroenterology2010
Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence.Current oncology (Toronto, Ont.) · 2025Observational
- Complications in Pericardiocentesis: Right Ventricular Perforation in a 75-Year-Old Patient with Lymphoma.The American journal of case reports · 2024Article
- Successful Management of Malignant Pericarditis Using Nivolumab for Metastatic Esophageal Squamous Cell Carcinoma.Internal medicine (Tokyo, Japan) · 2024Article
- Intrapericardial Cisplatin Instillation for Malignant Pericardial Effusion: A Single-center Experience.Arquivos brasileiros de cardiologia · 2023Article
- Constrictive pericarditis caused by pericardial metastasis from esophageal squamous cell carcinoma: a case report.International cancer conference journal · 2022Article
- Large Pericardial Effusion-Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage.Diagnostics (Basel, Switzerland) · 2022Article
- Review
- Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer.OncoTargets and therapy · 2018Article
- Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.Oncotarget · 2016Article
- Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.OncoTargets and therapy · 2015Article
- Constrictive pericarditis caused by a pericardial-occupying tumor due to esophageal cancer.Clinical journal of gastroenterology · 2014Article
- Response to neoplastic pericardial effusion.Clinical cardiology · 2012Article
- Neoplastic pericardial disease: Old and current strategies for diagnosis and management.World journal of cardiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the role and outcome of pericardiocentesis with intrapericardial cisplatin instillation for malignant pericardial effusion resulting from esophageal cancer.
methodsWe retrospectively studied 7 patients who underwent pericardiocentesis with intrapericardial cisplatin instillation for malignant pericardial effusion resulting from esophageal cancer. After pericardiocentesis, we performed catheterization of the pericardial space under ultrasonogram guidance. Malignant etiology of the pericardial fluid was confirmed by cytological examination. Subsequently, cisplatin (10 mg in 20 mL normal saline) was instilled into the pericardial space.
resultsThe mean total volume of the aspirated effusion fluid was 782 +/- 264 mL (range, 400-1200 mL). The drainage catheter was successfully removed in all patients, and the mean duration of pericardial drainage was 7.7 +/- 2.7 d (range, 5-13 d). No fluid reaccumulation was observed. Mean survival time was 120 +/- 71 d (range, 68-268 d).
conclusionPericardiocentesis along with catheter drainage appears to be a safe and effective for pericardial malignant effusion and tamponade, and cisplatin instillation prevents recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.